Kindeva to Invest US$42 million(£33m) to Enhance Inhaler Manufacturing in UK
Introduction:
Kindeva reveives an investment support of US$42 million(£33m) from the UK government to enhanc inhaler manufacturing and sustainability.
Features:
The investment facilitates inhaler manufacturing across two sites in the United Kingdom, specifically in Loughborough and Clitheroe.
The collaborative investment aims to enhance its ability to produce the next generation of environmentally-friendly pressurised metred-dose inhalers (pMDIs) and to provide ongoing advancements in treatments for respiratory illnesses on a global scale.
This financial support will enable to broaden its capabilities and production capacity. This expansion will involve pharmaceutical corporations worldwide to introduce the latest generation of green inhalers to the patients.
Furthermore, this investment supports:
- New manufacturing capability and capacity in Loughborough specifically geared towards manufacturing the next iteration of environmentally-friendly inhalers
- The site will make eco-conscious improvements to the supply chain of inhaler components at its Clitheroe site. This demonstrates a commitment to minimising the environmental footprint of the entire manufacturing process
- The investment will aid pharmaceutical firms in their transition towards greener practises, particularly in relation to their existing products. This transition will involve reducing emissions with a high global warming potential (GWP) and aligning with sustainability goals.
- The initiative also presents an opportunity to introduce innovative green inhalers and respiratory treatments to patients.
Specifications:
Name Kindeva
Type New Construction
Budget US$42 million(£33m)
